A linear lattice model for polyglutamine in CAG-expansion diseases

Huntington's disease and several other neurological diseases are caused by expanded polyglutamine [poly(Gln)] tracts in different proteins. Mechanisms for expanded (>36 Gln residues) poly(Gln) toxicity include the formation of aggregates that recruit and sequester essential cellular proteins [Preisinger, E., Jordan, B. M., Kazantsev, A. & Housman, D. (1999) Phil. Trans. R. Soc. London B 354, 1029–1034; Chen, S., Berthelier, V., Yang, W. & Wetzel, R. (2001) J. Mol. Biol. 311, 173–182] and functional alterations, such as improper interactions with other proteins [Cummings, C. J. & Zoghbi, H. Y. (2000) Hum. Mol. Genet. 9, 909–916]. Expansion above the “pathologic threshold” (≈36 Gln) has been proposed to induce a conformational transition in poly(Gln) tracts, which has been suggested as a target for therapeutic intervention. Here we show that structural analyses of soluble huntingtin exon 1 fusion proteins with 16 to 46 glutamine residues reveal extended structures with random coil characteristics and no evidence for a global conformational change above 36 glutamines. An antibody (MW1) Fab fragment, which recognizes full-length huntingtin in mouse brain sections, binds specifically to exon 1 constructs containing normal and expanded poly(Gln) tracts, with affinity and stoichiometry that increase with poly(Gln) length. These data support a “linear lattice” model for poly(Gln), in which expanded poly(Gln) tracts have an increased number of ligand-binding sites as compared with normal poly(Gln). The linear lattice model provides a rationale for pathogenicity of expanded poly(Gln) tracts and a structural framework for drug design.

[1]  A. Pastore,et al.  A structural approach to trinucleotide expansion diseases , 2001, Brain Research Bulletin.

[2]  Annalisa Pastore,et al.  Solution structure of polyglutamine tracts in GST‐polyglutamine fusion proteins , 2002, FEBS letters.

[3]  E. Harlow,et al.  Antibodies: A Laboratory Manual , 1988 .

[4]  M. MacDonald,et al.  Mutant Huntingtin Forms in Vivo Complexes with Distinct Context-Dependent Conformations of the Polyglutamine Segment , 1999, Neurobiology of Disease.

[5]  P. V. von Hippel,et al.  Calculation of protein extinction coefficients from amino acid sequence data. , 1989, Analytical biochemistry.

[6]  S. Warren,et al.  Genetic instabilities and hereditary neurological diseases , 1998 .

[7]  M. MacDonald,et al.  Huntingtin interacts with a family of WW domain proteins. , 1998, Human molecular genetics.

[8]  L. Weiner,et al.  Mutational analysis of the transferrin receptor reveals overlapping HFE and transferrin binding sites. , 2001, Journal of molecular biology.

[9]  S. Snyder,et al.  A huntingtin-associated protein enriched in brain with implications for pathology , 1995, Nature.

[10]  H. Zoghbi,et al.  Fourteen and counting: unraveling trinucleotide repeat diseases. , 2000, Human molecular genetics.

[11]  E. Altschuler,et al.  Random coil conformation for extended polyglutamine stretches in aqueous soluble monomeric peptides. , 2009, The journal of peptide research : official journal of the American Peptide Society.

[12]  D. Housman,et al.  Evidence for a recruitment and sequestration mechanism in Huntington's disease. , 1999, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[13]  H. Halvorson,et al.  Quantitative characterization of the thrombin-heparin interaction. Discrimination between specific and nonspecific binding models. , 1991, The Journal of biological chemistry.

[14]  P. V. von Hippel,et al.  DNA "melting" proteins. IV. Fluorescence measurements of binding parameters for bacteriophage T4 gene 32-protein to mono-, oligo-, and polynucleotides. , 1976, The Journal of biological chemistry.

[15]  S. W. Davies,et al.  Exon 1 of the HD Gene with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic Mice , 1996, Cell.

[16]  P. V. von Hippel,et al.  Theoretical aspects of DNA-protein interactions: co-operative and non-co-operative binding of large ligands to a one-dimensional homogeneous lattice. , 1974, Journal of molecular biology.

[17]  A. West,et al.  Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor(,). , 2000, Biochemistry.

[18]  J. Philo.  An improved function for fitting sedimentation velocity data for low-molecular-weight solutes. , 1997, Biophysical journal.

[19]  G. Fasman.  Circular Dichroism and the Conformational Analysis of Biomolecules , 1996, Springer US.

[20]  M. Saraste,et al.  FEBS Lett , 2000 .

[21]  H. Lehrach,et al.  Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Y. Agid,et al.  Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias , 1995, Nature.

[23]  J. M. Boutell,et al.  Aberrant interactions of transcriptional repressor proteins with the Huntington's disease gene product, huntingtin. , 1999, Human molecular genetics.

[24]  K. Wüthrich.  NMR of proteins and nucleic acids , 1988 .

[25]  Arthur J. Rowe,et al.  Analytical ultracentrifugation in biochemistry and polymer science , 1992 .

[26]  F. Young.  Biochemistry , 1955, The Indian Medical Gazette.

[27]  Jen-Tsi Yang,et al.  β-II conformation of all-β proteins can be distinguished from unordered form by circular dichroism , 1992 .

[28]  Hans Lehrach,et al.  Huntingtin-Encoded Polyglutamine Expansions Form Amyloid-like Protein Aggregates In Vitro and In Vivo , 1997, Cell.

[29]  M. MacDonald,et al.  Huntingtin: a single bait hooks many species , 1998, Current Opinion in Neurobiology.

[30]  P. Patterson,et al.  New anti-huntingtin monoclonal antibodies: implications for huntingtin conformation and its binding proteins , 2001, Brain Research Bulletin.

[31]  P. Chambon,et al.  The N‐terminal domain of the human TATA‐binding protein plays a role in transcription from TATA‐containing RNA polymerase II and III promoters. , 1994, The EMBO journal.

[32]  R. Wetzel,et al.  Polyglutamine aggregation behavior in vitro supports a recruitment mechanism of cytotoxicity. , 2001, Journal of molecular biology.

[33]  P. Hajduk,et al.  Discovering High-Affinity Ligands for Proteins: SAR by NMR , 1996, Science.

[34]  M. MacDonald,et al.  Amyloid Formation by Mutant Huntingtin: Threshold, Progressivity and Recruitment of Normal Polyglutamine Proteins , 1998, Somatic cell and molecular genetics.